Library · Metabolic & weight · Hypoparathyroidism
Yorvipath
Palopegteriparatide, TransCon PTH
FDA-approved in August 2024 as the first and only treatment for hypoparathyroidism in adults, this once-daily prodrug links PTH(1-34) to a branched PEG carrier via a proprietary linker, slowly releasing the hormone to maintain stable calcium levels without needing active vitamin D or high calcium doses.
Research score 90/100. Reference only, not a dose.
- Calcium Regulation
- Parathyroid Hormone Replacement
- US status
- Prescription Only
- Approval
- FDA Approved (2024)
- Evidence
- PaTHway Phase 3: 78.7% maintained normal calcium levels without conventional treatments vs 4.8% placebo (p<0.0001)
- Research score
- 90 / 100
- Indication
- Hypoparathyroidism in adults
- Origin
- United States
- Source category
- Bone & Musculoskeletal
- Status group
- Approved / prescription
Mechanism
The TransCon linker technology releases PTH(1-34) gradually over 24 hours, giving continuous hormone exposure that keeps serum calcium in the normal range.
Safety file
Generally well tolerated.
- Typical for PTH therapy - hypercalcemia if overdosed